The Experts below are selected from a list of 20706 Experts worldwide ranked by ideXlab platform
Henry Saffer - One of the best experts on this subject based on the ideXlab platform.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:Aims To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. Design Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. Measurements Mean monthly advertising exposures for households with televisions and adolescents aged 12‐17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban ® ; and other miscellaneous tobacco-related advertising.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:AIMS: To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. DESIGN: Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. MEASUREMENTS: Mean monthly advertising exposures for households with televisions and adolescents aged 12-17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban; and other miscellaneous tobacco-related advertising. FINDINGS: Combined tobacco Company youth/parent advertising exposures matched those for combined State/Legacy campaigns (4.56 advertisements/month versus 4.97 advertisements/month among households; 3.05 advertisements/month versus 3.38 advertisements/month among adolescents). Tobacco Company corporate image advertising averaged 3.25 advertisements/month among households and 0.73 advertisements/month among adolescents. Tobacco Company advertising exceeded public health-sponsored advertising by a factor of 1.57-1, and among youth by 1.11-1. Pharmaceutical companies were the largest sponsor of tobacco-related advertising for households (10.37 advertisements/month) and provided significant exposure among adolescents (2.61 advertisements/month). CONCLUSIONS: This is the first study to demonstrate systematically that public health-sponsored antitobacco campaigns in the United States are matched or exceeded by tobacco Company advertising, as well as Pharmaceutical cessation product advertising. Research is needed to determine whether such advertising may dilute or undermine the established benefits of tobacco control-sponsored campaigns.
Dave H Schweitzer - One of the best experts on this subject based on the ideXlab platform.
-
premature ejaculation and Pharmaceutical Company based medicine the dapoxetine case
The Journal of Sexual Medicine, 2008Co-Authors: Marcel D Waldinger, Dave H SchweitzerAbstract:ABSTRACT Introduction The manufacturer of dapoxetine funded randomized clinical trials to study its effect in premature ejaculation (PE). Financial support by Pharmaceutical companies, however, may jeopardize the neutrality of clinical research. Aim To investigate the scientific process that has been followed in dapoxetine treatment trials and reviews as compared to daily drug treatment trials and reviews with selective serotonin reuptake inhibitors (SSRIs) in men with PE. Methods A search of Medline and Embase was conducted using the search terms “dapoxetine” or “SSRI.” References of retrieved articles were searched. Only studies describing the use of these drugs in men with PE were included. Main Outcome Measures Compared fold-increase intravaginal ejaculation latency time (IELT), geometric mean IELT, and adverse effect profiles between dapoxetine and SSRIs in PE. Results Preclinical studies on dapoxetine, including a multicenter study (category A) and reviews (category B), were compared with clinical studies with daily conventional SSRIs in PE (category C). Categories A/B focused on patient-reported outcomes with less attention for the IELT. The ejaculation-delaying effect of dapoxetine was expressed as natural mean IELT rather than as geometrical mean IELT. Dapoxetine side effects were monthly scored. In contrast, a significant part of category C articles focused on IELT data, used geometric mean IELT outcomes, and one study reported the side effects measured 24–48 hours after drug intake using a validated questionnaire. Without the Food and Drug Administration approval, dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE. However, the off-label use of dapoxetine has never been criticized by clinical investigators in contrast to commentaries against the off-label use of daily SSRI treatment in PE. Conclusions Manufacturer-funded drug treatment research (categories A and B) is advantageously treated by some authors as compared with nonfunded trials with daily conventional SSRIs (category C). PE drug treatment research is a young and dynamic field, and its development deserves transparency to its development. Waldinger MD, and Schweitzer DH. Premature ejaculation and Pharmaceutical Company-based medicine: The dapoxetine case.
-
premature ejaculation and Pharmaceutical Company based medicine the dapoxetine case
The Journal of Sexual Medicine, 2008Co-Authors: Marcel D Waldinger, Dave H SchweitzerAbstract:ABSTRACT Introduction The manufacturer of dapoxetine funded randomized clinical trials to study its effect in premature ejaculation (PE). Financial support by Pharmaceutical companies, however, may jeopardize the neutrality of clinical research. Aim To investigate the scientific process that has been followed in dapoxetine treatment trials and reviews as compared to daily drug treatment trials and reviews with selective serotonin reuptake inhibitors (SSRIs) in men with PE. Methods A search of Medline and Embase was conducted using the search terms “dapoxetine” or “SSRI.” References of retrieved articles were searched. Only studies describing the use of these drugs in men with PE were included. Main Outcome Measures Compared fold-increase intravaginal ejaculation latency time (IELT), geometric mean IELT, and adverse effect profiles between dapoxetine and SSRIs in PE. Results Preclinical studies on dapoxetine, including a multicenter study (category A) and reviews (category B), were compared with clinical studies with daily conventional SSRIs in PE (category C). Categories A/B focused on patient-reported outcomes with less attention for the IELT. The ejaculation-delaying effect of dapoxetine was expressed as natural mean IELT rather than as geometrical mean IELT. Dapoxetine side effects were monthly scored. In contrast, a significant part of category C articles focused on IELT data, used geometric mean IELT outcomes, and one study reported the side effects measured 24–48 hours after drug intake using a validated questionnaire. Without the Food and Drug Administration approval, dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE. However, the off-label use of dapoxetine has never been criticized by clinical investigators in contrast to commentaries against the off-label use of daily SSRI treatment in PE. Conclusions Manufacturer-funded drug treatment research (categories A and B) is advantageously treated by some authors as compared with nonfunded trials with daily conventional SSRIs (category C). PE drug treatment research is a young and dynamic field, and its development deserves transparency to its development. Waldinger MD, and Schweitzer DH. Premature ejaculation and Pharmaceutical Company-based medicine: The dapoxetine case.
Frank J Chaloupka - One of the best experts on this subject based on the ideXlab platform.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:Aims To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. Design Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. Measurements Mean monthly advertising exposures for households with televisions and adolescents aged 12‐17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban ® ; and other miscellaneous tobacco-related advertising.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:AIMS: To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. DESIGN: Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. MEASUREMENTS: Mean monthly advertising exposures for households with televisions and adolescents aged 12-17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban; and other miscellaneous tobacco-related advertising. FINDINGS: Combined tobacco Company youth/parent advertising exposures matched those for combined State/Legacy campaigns (4.56 advertisements/month versus 4.97 advertisements/month among households; 3.05 advertisements/month versus 3.38 advertisements/month among adolescents). Tobacco Company corporate image advertising averaged 3.25 advertisements/month among households and 0.73 advertisements/month among adolescents. Tobacco Company advertising exceeded public health-sponsored advertising by a factor of 1.57-1, and among youth by 1.11-1. Pharmaceutical companies were the largest sponsor of tobacco-related advertising for households (10.37 advertisements/month) and provided significant exposure among adolescents (2.61 advertisements/month). CONCLUSIONS: This is the first study to demonstrate systematically that public health-sponsored antitobacco campaigns in the United States are matched or exceeded by tobacco Company advertising, as well as Pharmaceutical cessation product advertising. Research is needed to determine whether such advertising may dilute or undermine the established benefits of tobacco control-sponsored campaigns.
Melanie Wakefield - One of the best experts on this subject based on the ideXlab platform.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:Aims To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. Design Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. Measurements Mean monthly advertising exposures for households with televisions and adolescents aged 12‐17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban ® ; and other miscellaneous tobacco-related advertising.
-
mixed messages on tobacco comparative exposure to public health tobacco Company and Pharmaceutical Company sponsored tobacco related television campaigns in the united states 1999 2003
Addiction, 2005Co-Authors: Melanie Wakefield, Glen Szczypka, Yvonne M Terrymcelrath, Sherry Emery, Brian R Flay, Frank J Chaloupka, Henry SafferAbstract:AIMS: To describe and compare the extent of exposure among youth and adults to antitobacco advertising funded by tobacco control agencies, and to smoking-related advertising from tobacco and Pharmaceutical companies. DESIGN: Archival records of television advertising exposures from Nielsen Media Research for the largest 75 media markets in the United States from 1999 to 2003. MEASUREMENTS: Mean monthly advertising exposures for households with televisions and adolescents aged 12-17 years for: state tobacco control programs; the national American Legacy Foundation (Legacy) program; tobacco Company advertising for youth smoking prevention, parent advertising and corporate image; Pharmaceutical Company advertising for nicotine replacement therapy and Zyban; and other miscellaneous tobacco-related advertising. FINDINGS: Combined tobacco Company youth/parent advertising exposures matched those for combined State/Legacy campaigns (4.56 advertisements/month versus 4.97 advertisements/month among households; 3.05 advertisements/month versus 3.38 advertisements/month among adolescents). Tobacco Company corporate image advertising averaged 3.25 advertisements/month among households and 0.73 advertisements/month among adolescents. Tobacco Company advertising exceeded public health-sponsored advertising by a factor of 1.57-1, and among youth by 1.11-1. Pharmaceutical companies were the largest sponsor of tobacco-related advertising for households (10.37 advertisements/month) and provided significant exposure among adolescents (2.61 advertisements/month). CONCLUSIONS: This is the first study to demonstrate systematically that public health-sponsored antitobacco campaigns in the United States are matched or exceeded by tobacco Company advertising, as well as Pharmaceutical cessation product advertising. Research is needed to determine whether such advertising may dilute or undermine the established benefits of tobacco control-sponsored campaigns.
S Priyan - One of the best experts on this subject based on the ideXlab platform.
-
optimal inventory management strategies for Pharmaceutical Company and hospital supply chain in a fuzzy stochastic environment
Operations research for health care, 2014Co-Authors: S Priyan, R UthayakumarAbstract:Abstract Pharmaceutical plays a crucial role in the healthcare industries due to the significant costs of the products and their storage and control requirements. It can be expensive to purchase and distribute. An effective management of Pharmaceutical is required to ensure the 100% product availability at the right time, at the right cost, in good condition to right customers. Uthayakumar and Priyan (2013) proposed an integrated inventory model for Pharmaceutical products in a two-echelon supply chain consisting of a Pharmaceutical Company and a hospital. They offered strategic decision-making to achieve the target customer service level of the hospital at minimum supply chain cost. In this paper we extend their model to reflect the following three facts: (i) fuzzify the hospital’s expiry rate ( d b i ) and holding cost ( h b i ) , and the Pharmaceutical Company’s production rate ( P i ) , screening rate ( r s i ) , holding cost ( h w i ) and selling price ( s d i ) for the i th product as the triangular fuzzy numbers in the total cost, (ii) hospital’s quantity received does not necessarily match with the ordered quantity due to various reasons, i.e., the received quantity is uncertain, but it is a random variable following a normal distribution, and (iii) the lead time L consists of m mutually independent components. We then used the signed distance method to defuzzify the fuzzy total cost of the system and Uthayakumar and Priyan’s (2013) Lagrangian multiplier approach to determine the optimal solution of the proposed model. Numerical example is given to highlight the differences between crisp and the fuzzy cases.
-
Pharmaceutical supply chain and inventory management strategies optimization for a Pharmaceutical Company and a hospital
Operations research for health care, 2013Co-Authors: R Uthayakumar, S PriyanAbstract:Abstract A high level of service for medical supplies and effective inventory policies are essential objectives for all health care industries. Medicine shortages and improper use of Pharmaceuticals can not only lead to financial losses but also have a significant impact on patients. Many health systems and hospitals experience difficulties in achieving these goals as they have not addressed how medicines are managed, supplied, and used to save lives and improve health. Studies are essential to understand operations in health care industries and to offer decision support tools that improve health policy, public health, patient safety, and strategic decision-making in the Pharmaceutical supply chain. We present an inventory model that integrates continuous review with production and distribution for a supply chain involving a Pharmaceutical Company and a hospital supply chain. The model considers multiple Pharmaceutical products, variable lead time, permissible payment delays, constraints on space availability, and the customer service level (CSL). We develop a procedure for determining optimal solutions for inventory lot size, lead time, and the number of deliveries to achieve hospital CSL targets with a minimum total cost for the supply chain. A numerical example illustrates the model application and behavior.